|
|
Article: Dynavax Announces Completion of Enrollment in TOLAMBA(TM) Ragweed Allergy Trial.
- Article from:
- PR Newswire
- Article date:
- June 7, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Physician and Patient Demand Led to Accelerated Recruitment of More Than 700 Subjects
BERKELEY, Calif., June 7 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation announced that enrollment in the Dynavax Allergic Rhinitis TOLAMBA Trial (DARTT) has exceeded expectations relative to the speed and number of study subjects. More than 700 subjects were enrolled in the study in less than eight weeks, prompting Dynavax to close enrollment early. Enrollment in the DARTT study has been completed and all subjects have been randomized. The company believes that strong investigator and patient interest in TOLAMBA as a potentially disease-modifying allergy ...